文献速递胸部肿瘤放疗放疗物理与技术

心脏亚结构剂量与非癌死亡关联模型在早期NSCLC SBRT中的外部验证

External validation of dose to heart substructures and the association with non-cancer death after SBRT in stage I-II NSCLC patients.
PubMed 文献 · Radiother Oncol · 2026-07-26

该研究利用两个独立队列(221例和217例)对已发表的预测早期非小细胞肺癌(NSCLC)接受立体定向体部放疗(SBRT)后非癌死亡(nonCAdeath)与心脏剂量关联的模型进行外部验证。结果显示,该模型在非癌死亡定义相似的队列中得以泛化,平行建立的总生存模型在两个队列中均得到验证;列线图提示高心脏剂量(22 Gy)患者若心脏剂量降低36%,24个月非癌死亡风险可降低1%。

要点

  • 已发表的非癌死亡模型在定义相似的队列中外部验证成功。
  • 以总生存为终点的平行模型在两个验证队列中均得到验证。
  • 列线图显示高心脏剂量患者降低心脏剂量可小幅减少24个月非癌死亡风险。

核心结论

  • 描述心脏剂量参数、基线临床参数与SBRT后非癌死亡关联的模型在结局定义相似的队列中获得外部验证。
  • 以总生存为终点的平行模型在两个验证队列中均得到验证,增强了非癌死亡模型指导心脏保护的稳健性。

研究设计与样本

  • 采用两个独立验证队列(分别221例和217例早期NSCLC患者)对已发表的Cox非癌死亡模型进行外部验证,重点评估校准度和区分度。
  • 基于非癌死亡模型构建列线图以评估24个月时的临床影响。
  • 使用原始推导队列(N=803)构建总生存模型并进行验证,以处理结局定义的差异。

主要发现

  • 已发表的非癌死亡模型在一个非癌死亡定义相似的队列中得以泛化,平行总生存模型在两个队列中均得到验证。
  • 推导队列与验证队列间的预后指数无显著差异,三个队列间的区分度相当。
  • 在验证成功的队列中,预测值与观察生存重叠良好,风险组的风险比在推导与验证队列间相当。
  • 列线图提示,对于心脏剂量较高(22 Gy)的平均患者,心脏剂量降低36%可使24个月非癌死亡风险降低1%。

关键数值与推荐

  • 已发表模型包含年龄、体能状态、基线肺功能、基线心脏状况以及左心房和上腔静脉剂量。
  • 列线图示例:平均患者心脏剂量22 Gy时,心脏剂量降低36%对应24个月非癌死亡风险降低1%。

临床怎么用

  • 该外部验证结果支持在SBRT计划中参考非癌死亡模型进行心脏亚结构剂量保护。
  • 列线图可用于评估24个月非癌死亡风险及心脏剂量降低的潜在获益。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We use two independent cohorts to externally validate a published model describing the association between non-cancer death (nonCAdeath) and cardiac dose in patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). METHODS: The published model included age, performance status, baseline lung function, baseline cardiac condition, and dose to the left atrium and superior vena cava. The two validation cohorts consisted of 221 and 217 early-stage NSCLC patients. Validation of the Cox-based nonCAdeath model focused on assessing calibration and discrimination. A nomogram was built based on the nonCAdeath model to assess clinical impact at 24 months. In parallel, to account for discrepancies in outcome definition, an overall survival model was built using the original derivation cohort (N = 803) and validated as well. RESULTS: the published nonCAdeath model generalized in one cohort with similar nonCAdeath definition, and the parallel overall survival model validated in both cohorts; the prognostic index was not significantly different between the derivation cohort and validation cohorts, discrimination was comparable across all three cohorts. For the cohorts that validated, the predictions overlapped well with the observed survival, and Hazard ratios for risk groups were comparable between derivation and validation cohorts. The nomogram indicates that for an average patient with a high cardiac dose (22 Gy), a 36% cardiac dose reduction could decrease the risk of nonCAdeath at 24 months by 1%. CONCLUSION: The model that describes the association between cardiac dose parameters, baseline clinical parameters and nonCAdeath after SBRT was externally validated in the cohort with similar outcome definition, while the parallel model with overall survival as endpoint validated in both cohorts. The results from this observational validation study strengthen the robustness of the nonCAdeath model guidance for cardiac sparing.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Stam B, Wijsman R, Thor M, et al. External validation of dose to heart substructures and the association with non-cancer death after SBRT in stage I-II NSCLC patients. Radiother Oncol. 2026. PMID: 42503335. doi:10.1016/j.radonc.2026.111713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。